November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at firstname.lastname@example.org)
December 07, 2016
Israeli ambassador Heifetz ends stint in Moscow, to represent country in Beijing from January - diplomatic mission
Contact group orders preparations for release of maximal number of prisoners in Donbas before New Year holidays - Kyiv
Next meeting of Contact Group in Minsk scheduled for Dec 21
Moldovan president-elect to seek resignation of prosecutor general to be appointed by outgoing president
Ukrainian army shelling cuts electricity supply at Donetsk water filtering station, water supply disrupted - DPR
Higher oil prices in 2017 could bring in an additional 1 trln rubles, part to go toward spending - Siluanov
Gorbachev calls Belavezha Accords participants led by then-leadership of Russia culprits of USSR break-up
Russian Eurobonds up moderately on gains for UST
Gorbachev confident conditions exist for development of good-neighborly relations with Japan, 'but not at the expense of trade in territories'
Lukoil shareholders accept 9M dividend of 75 rubles a share
Kazakh parliament votes for fingerprinting all citizens aged 16 and over, foreigners seeking visas
Kyiv continues to disregard all instructions from Contact Group, 'Normandy format' foreign ministers - Donetsk
Ingushetia's counter-extremism chief, several subordinates detained - source